GE beefs up life sciences division with $1.06B Thermo Fisher deal

GE Healthcare CEO John Dineen

GE Healthcare is expanding its footprint in the life sciences industry, snapping up the cell culture, gene modulation and magnetic bead business of Thermo Fisher Scientific for a bit more than a billion dollars. GE plans to add the technologies to its life sciences unit.

Thermo Fisher offered GE the chance to beef up its work serving the drug discovery and manufacturing fields as Thermo Fisher follows through with a divestiture program aimed at gaining the European Commission's final OK to buy out Life Technologies.

The deal will add Thermo Fisher's Hyclone cell culture media and sera products, which GE says will fit in nicely with its existing work in cell biology research and biomanufacturing. The gene modulation technologies can be added to GE's offerings to investigators while the magnetic beads will expand its presence in protein analysis and medical diagnostics. Altogether, these products delivered $250 million in sales revenue last year.

GE Healthcare CEO John Dineen touted the deal in a statement as a big plus. "Life Sciences is one of our strongest and fastest-growing business areas, driven by the world's demand for improved diagnostics and new, safer medicines. Combining GE's engineering expertise with our capabilities in life sciences is already bringing great benefits to industry, research and patients."

- here's the release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.